A perspective on metabolic syndrome and nonalcoholic fatty liver disease

Metabolic Syndrome and Related Disorders

Volumn 13, Issue 6, 2015, Pages 235-238

  Targher, Giovanni ^a   Byrne, Christopher D ^b,c  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OMEGA 3 FATTY ACID; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3; PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; ADIPONUTRIN, HUMAN; BIOLOGICAL MARKER; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE;

DISEASE ASSOCIATION; DISEASE SEVERITY; FAT CONTENT; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HISTOLOGY; HOMOZYGOSITY; HUMAN; LIPOLYSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; BLOOD; DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; INSULIN RESISTANCE; NON-ALCOHOLIC FATTY LIVER DISEASE; PHENOTYPE; PROGNOSIS; PROTECTION; RISK ASSESSMENT; RISK FACTOR;

BIOMARKERS; DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; INSULIN RESISTANCE; LIPASE; MEMBRANE PROTEINS; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; PHENOTYPE; PROGNOSIS; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS;

EID: 84930669265     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2015.1502     Document Type: Review

References (45)

1. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10:330-344.
2. Targher G, Byrne CD. Clinical review: Nonalcoholic fatty liver disease: A novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 2013; 98:483-495.
3. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363:1341-1350.
4. Lonardo A, Ballestri S, Marchesini G, et al. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Dig Liv Dis 2014; doi: http://dx.doi.org/10.10167j.dld.2014.09.020.
5. Fraser A, Harris R, Sattar N, et al. Alanine aminotrans-ferase, gamma-glutamyltransferase, and incident diabetes: The British Women's Heart and Health Study and metaanalysis. Diabetes Care 2009; 32:741-750.
6. Balkau B, Lange C, Vol S, et al.; Group Study D.E.S.I.R. Nine-year incident diabetes is predicted by fatty liver indices: The French D.E.S.I.R. study. BMC Gastroenterol 2010; 10:56.
7. Shibata M, Kihara Y, Taguchi M, et al. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007; 30:2940-2944.
8. Yamada T, Fukatsu M, Suzuki S, et al. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010; 25:352-356.
9. Bae JC, Rhee EJ, Lee WY, et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: A 4-year retrospective longitudinal study. Diabetes Care 2011; 34:727-729.
10. Chon CW, Kim BS, Cho YK, et al. Effect of nonalcoholic fatty liver disease on the development of type 2 diabetes in non-obese, nondiabetic Korean men. Gut Liver 2012; 6:368-373.
11. Choi JH, Rhee EJ, Bae JC, et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: A 4-year longitudinal study. Arch Med Res 2013; 44:115-120.
12. Chang Y, Jung HS, Yun KE, et al. Cohort study of nonalcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am J Gastroenterol 2013; 108:1861-1868.
13. Park SK, Seo MH, Shin HC, et al. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-Year prospective cohort study. Hepatology 2013; 57:1378-1383.
14. Sung KC, Jeong WS, Wild SH, et al. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 2012; 35: 717-722.
15. Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab 2013; 98: 3637-3643.
16. Jo SK, Lee WY, Rhee EJ, et al. Serum gamma-glutamyl transferase activity predicts future development of metabolic syndrome defined by 2 different criteria. Clin Chim Acta 2009; 403:234-240.
17. Adams LA, Waters OR, Knuiman MW, et al. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: An eleven-year follow-up study. Am J Gastroenterol 2009; 104:861-867.
18. Xu Y, Bi YF, Xu M, et al. Cross-sectional and longitudinal association of serum alanine aminotransaminase and g-glutamyltransferase with metabolic syndrome in middle-aged and elderly Chinese people. J Diabetes 2011; 3:38-47.
19. Liu CF, Zhou WN, Fang NY. Gamma-glutamyltransferase levels and risk of metabolic syndrome: A meta-analysis of prospective cohort studies. Int J Clin Pract 2012; 66:692-698.
20. Ryoo JH, Choi JM, Moon SY, et al. The clinical availability of non alcoholic fatty liver disease as an early predictor of the metabolic syndrome in Korean men: 5-Year's prospective cohort study. Atherosclerosis 2013; 227:398-403.
21. Suh YJ, Park SK, Choi JM, et al. The clinical importance of serum g-glutamyltransferase level as an early predictor of obesity development in Korean men. Atherosclerosis 2013; 227:437-441.
22. Cicero AF, D'Addato S, Reggi A, et al.; Brisighella Heart Study. Gender difference in hepatic steatosis index and li-pid accumulation product ability to predict incident metabolic syndrome in the historical cohort of the Brisighella Heart Study. Metab Syndr Relat Disord 2013; 11:412-416.
23. Ryoo JH, Oh CM, Kim HS, et al. Clinical association between serum g-glutamyltransferase levels and the development of insulin resistance in Korean men: A 5-year follow-up study. Diabet Med 2014; 31:455-461.
24. Sung KC, Wild SH, Byrne CD. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow up, and risk of incident hypertension. J Hepatol 2014; 60:1040-1045.
25. Amaro A, Fabbrini E, Kars M, et al. Dissociation between in-trahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 2010; 139:149-153.
26. Kantartzis K, Peter A, Machicao F, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009; 58:2616-2623.
27. Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. He-patology 2014; 59:713-723.
28. Perry RJ, Samuel VT, Petersen KF, et al. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 2014; 510:84-91.
29. Sung KC, Cha SC, Sung JW, et al. Metabolically healthy obese subjects are at risk of fatty liver but not of pre-clinical atherosclerosis. Nutr Metab Cardiovasc Dis 2014; 24:256-262.
30. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40:1461-1465.
31. Mashek DG, Greenberg AS. Serum TAG analysis differentiates between genetic and obesity-associated NAFLD. Diabetes 2014; 63:42-44.
32. Hyysalo J Gopalacharyulu P, Bian H, et al. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity. Diabetes 2014; 63:312-322.
33. Petta S, Valenti L, Marchesini G, et al. PNPLA3 GG genotype and carotid atherosclerosis in patients with nonalcoholic fatty liver disease. PLoS One 2013; 8:e74089.
34. Farrell GC. PNPLeAse get the fats right: Does lipogenesis or lipolysis cause NASH? Hepatology 2010; 52:818-821.
35. Smagris E, BasuRay S, Li J, et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 2015; 61:108-118.
36. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histo-logical severity of nonalcoholic fatty liver disease. Hepatology 2011; 53:1883-1894.
37. Qiao A, Liang J, Ke Y, et al. Mouse patatin-like phos-pholipase domain-containing 3 influences systemic lipid and glucose homeostasis. Hepatology 2011; 54:509-521.
38. Ruhanen H, Perttila J, Holtta-Vuori M, et al. PNPLA3 mediates hepatocyte triacylglycerol remodeling. J Lipid Res 2014; 55:739-746.
39. Nobili V, Bedogni G, Donati B, et al. The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease. J Med Food 2013; 16:957-960.
40. Shearer GC, Savinova OV, Harris WS. Fish oil-How does it reduce plasma triglycerides? Biochim Biophys Acta 2012; 1821:843-851.
41. Scorletti E, Bhatia L, McCormick KG, et al.; on behalf of the WELCOME Study Investigators. Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: Results from the WELCOME study. Hepatology 2014; 60:1211-1221.
42. Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008; 40:194-199.
43. Maitin V, Andreo U, Guo L, et al. Docosahexaenoic acid impairs the maturation of very low density lipoproteins in rat hepatic cells. J Lipid Res 2014; 55:75-84.
44. Tanaka N, Zhang X, Sugiyama E, et al. Eicosapentaenoic acid improves hepatic steatosis independent of PPAR-alpha activation through inhibition of SREBP-1 maturation in mice. Biochem Pharmacol 2010; 80:1601-1612.
45. Scorletti E, Byrne CD. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr 2013; 33:231-248.